Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain
Jingyi Bai,Xi Li,Jun Zhao,Huifang Zong,Yuan Yuan,Lei Wang,Xiaoshuai Zhang,Yong Ke,Lei Han,Jianrong Xu,Buyong Ma,Baohong Zhang,Jianwei Zhu
DOI: https://doi.org/10.3390/ijms25031593
IF: 5.6
2024-01-28
International Journal of Molecular Sciences
Abstract:Amyloidosis involves the deposition of misfolded proteins. Even though it is caused by different pathogenic mechanisms, in aggregate, it shares similar features. Here, we tested and confirmed a hypothesis that an amyloid antibody can be engineered by a few mutations to target a different species. Amyloid light chain (AL) and β-amyloid peptide (Aβ) are two therapeutic targets that are implicated in amyloid light chain amyloidosis and Alzheimer's disease, respectively. Though crenezumab, an anti-Aβ antibody, is currently unsuccessful, we chose it as a model to computationally design and prepare crenezumab variants, aiming to discover a novel antibody with high affinity to AL fibrils and to establish a technology platform for repurposing amyloid monoclonal antibodies. We successfully re-engineered crenezumab to bind both Aβ42 oligomers and AL fibrils with high binding affinities. It is capable of reversing Aβ42-oligomers-induced cytotoxicity, decreasing the formation of AL fibrils, and alleviating AL-fibrils-induced cytotoxicity in vitro. Our research demonstrated that an amyloid antibody could be engineered by a few mutations to bind new amyloid sequences, providing an efficient way to reposition a therapeutic antibody to target different amyloid diseases.
biochemistry & molecular biology,chemistry, multidisciplinary